CFT8634 is a degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors[1].
[1]. Nasveschuk CG, et, al. Compounds for targeted degradation of brd9. WO2021178920A1.
















